Merck's antibody-drug conjugate sac-TMT just became the first ADC to beat chemotherapy on both overall survival and progression-free survival in advanced endometrial cancer. For patients who'd exhausted chemo and immunotherapy, this Phase 3 win could rewrite the treatment playbook.
For decades, women with advanced endometrial cancer who'd already tried chemotherapy and immunotherapy faced a grim reality: pick between two mediocre chemo drugs and hope for the best. No targeted therapy had ever beaten standard chemo in a global Phase 3 trial for this group. That just changed.
Merck announced that its antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT for short) hit both primary goals in the Phase 3 TroFuse-005 trial. The drug showed statistically significant improvements in overall survival and progression-free survival compared to physician's-choice chemotherapy. It also posted a higher response rate as a secondary endpoint. No new safety concerns popped up.
This is a first. Not just for Merck, but for the entire ADC drug class in endometrial cancer.
Why This Disease Has Been So Stubborn
Endometrial cancer is the sixth most common cancer diagnosed in women worldwide, with roughly 417,000 new cases and 97,000 deaths recorded globally in 2020. Those numbers are climbing, driven by aging populations and rising obesity rates.
Most patients catch it early and do fine. But for the subset who present with advanced disease or relapse after initial treatment, the outlook darkens fast. First-line therapy today means carboplatin-paclitaxel plus an immune checkpoint inhibitor like pembrolizumab. That's a real upgrade from a few years ago.
The problem comes after. When patients progress through both chemo and immunotherapy, the cupboard is nearly bare. Doctors can offer single-agent doxorubicin or paclitaxel (think: recycling the same playbook with diminishing returns) or the combination of pembrolizumab plus lenvatinib, which works but carries significant toxicity. About 29% of patients on lenvatinib-pembrolizumab experience serious treatment-related adverse events, and roughly 39% discontinue treatment because of them.
That's the gap sac-TMT is trying to fill: a targeted therapy for patients who've already burned through the big guns.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
ADCs are one of the hottest drug classes in oncology right now, and the concept is elegant. Think of them as guided missiles: an antibody finds a specific target on cancer cells, locks on, and delivers a toxic payload directly inside. The idea is to kill tumor cells while sparing healthy tissue that traditional chemo would damage.
Sac-TMT targets a protein called TROP2, which is overexpressed on the surface of many solid tumors. The antibody carries a belotecan-derived payload (a topoisomerase I inhibitor, which essentially causes lethal DNA damage). What makes this ADC interesting from an engineering standpoint is its unusually high drug-to-antibody ratio of about 7.4, meaning each antibody molecule hauls nearly twice the payload of some competitors. A novel linker chemistry keeps the drug stable in the bloodstream but releases it once inside tumor cells.
The drug also produces what scientists call a "bystander effect." Once released inside one cancer cell, the payload can leak into neighboring tumor cells, even those that don't express much TROP2. It's less like a sniper rifle and more like a grenade lobbed into a foxhole.
What the Trial Actually Showed
TroFuse-005 enrolled 776 patients across multiple countries. All had advanced or recurrent endometrial carcinoma (or the aggressive subtype carcinosarcoma) and had already received both platinum-based chemo and a PD-1/PD-L1 inhibitor. They were randomized to either sac-TMT or the doctor's choice of doxorubicin or paclitaxel.
At a pre-specified interim analysis, sac-TMT cleared both co-primary endpoints: overall survival and progression-free survival (as measured by blinded independent central review). Merck called the improvements "statistically significant and clinically meaningful."
One important caveat: Merck hasn't released the actual numbers yet. No hazard ratios, no median survival figures, no Kaplan-Meier curves. The company says full data will be presented at an upcoming medical conference, likely later in 2026. Until we see those details, we can't size the magnitude of benefit; we just know it crossed the statistical bar.
Wall Street's Verdict: Encouraging, Not Euphoric
Analysts greeted the news positively but with measured enthusiasm. The consensus framing is that TroFuse-005 de-risks a key pillar of Merck's post-Keytruda strategy without single-handedly transforming the company's outlook.
That context matters. Keytruda (pembrolizumab) is Merck's blockbuster immunotherapy and the company's single biggest revenue driver. As it approaches loss of exclusivity, Merck needs new growth engines. Sac-TMT, with 17 ongoing Phase 3 trials across more than nine tumor types and over 15,000 patients enrolled globally, represents one of the broadest bets in the ADC space.
Guggenheim noted "growing investor interest" in sac-TMT and said the positive result should "only increase that enthusiasm." But most sell-side commentary emphasized that the real valuation impact depends on the magnitude of benefit (those missing numbers again) and how regulators respond.
Merck has stated it plans to share data and discuss results with regulatory authorities, though the company hasn't committed to a specific filing timeline.
The Bigger Picture: ADCs Are Storming Gynecologic Cancers
Sac-TMT isn't entering an empty arena. The ADC landscape in women's cancers is getting crowded fast. Tisotumab vedotin is the established ADC in cervical cancer, while mirvetuximab soravtansine holds the lead in ovarian cancer.
What makes sac-TMT's win notable is scope. TROP2 is widely expressed across endometrial tumors regardless of HER2 status, which means the addressable patient population is potentially much larger. And Merck isn't stopping here: a second endometrial trial, TroFuse-033, is already underway testing sac-TMT as first-line maintenance therapy in the roughly 70-75% of endometrial cancers classified as pMMR (mismatch-repair proficient), the subgroup that benefits least from immunotherapy alone. That trial is enrolling approximately 900 patients, with results expected around 2032.
The shift happening in gynecologic oncology mirrors what ADCs already did in breast cancer: moving from niche, biomarker-selected populations toward broader use across disease subtypes and treatment lines.
What to Watch Next
The full data presentation is the main event. Conference season later this year (think ESMO) should reveal whether sac-TMT's survival benefit is modest or practice-changing. Until then, the headline is simple: for women with advanced endometrial cancer who had run out of good options, there's now a targeted therapy that beat chemo in a rigorous global trial.
That's never happened before.
Deals & M&A
4 min read
Lilly Just Bet $3 Billion on a Chinese Pharma You've Never Heard Of
Eli Lilly just committed up to $3 billion to partner with a Chinese drugmaker most Western investors have never heard of. The deal covers five undisclosed drug programs, and the secrecy is almost as interesting as the price tag.
